141 related articles for article (PubMed ID: 24491461)
1. A radiogallium-DOTA-based bivalent peptidic ligand targeting a chemokine receptor, CXCR4, for tumor imaging.
Sano K; Masuda R; Hisada H; Oishi S; Shimokawa K; Ono M; Fujii N; Saji H; Mukai T
Bioorg Med Chem Lett; 2014 Mar; 24(5):1386-8. PubMed ID: 24491461
[TBL] [Abstract][Full Text] [Related]
2. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
3. Design of Ga-DOTA-based bifunctional radiopharmaceuticals: two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability.
Mukai T; Suwada J; Sano K; Okada M; Yamamoto F; Maeda M
Bioorg Med Chem; 2009 Jul; 17(13):4285-9. PubMed ID: 19481944
[TBL] [Abstract][Full Text] [Related]
4. Novel Peptide-Based PET Probe for Non-invasive Imaging of C-X-C Chemokine Receptor Type 4 (CXCR4) in Tumors.
Trotta AM; Aurilio M; D'Alterio C; Ieranò C; Di Martino D; Barbieri A; Luciano A; Gaballo P; Santagata S; Portella L; Tomassi S; Marinelli L; Sementa D; Novellino E; Lastoria S; Scala S; Schottelius M; Di Maro S
J Med Chem; 2021 Mar; 64(6):3449-3461. PubMed ID: 33660512
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.
Demmer O; Dijkgraaf I; Schumacher U; Marinelli L; Cosconati S; Gourni E; Wester HJ; Kessler H
J Med Chem; 2011 Nov; 54(21):7648-62. PubMed ID: 21905730
[TBL] [Abstract][Full Text] [Related]
6. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging.
Sano K; Okada M; Hisada H; Shimokawa K; Saji H; Maeda M; Mukai T
Biol Pharm Bull; 2013; 36(4):602-8. PubMed ID: 23546294
[TBL] [Abstract][Full Text] [Related]
7. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of 68Ga-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers.
Hoigebazar L; Jeong JM; Hong MK; Kim YJ; Lee JY; Shetty D; Lee YS; Lee DS; Chung JK; Lee MC
Bioorg Med Chem; 2011 Apr; 19(7):2176-81. PubMed ID: 21419635
[TBL] [Abstract][Full Text] [Related]
9. C-terminal-modified LY2510924: a versatile scaffold for targeting C-X-C chemokine receptor type 4.
Suzuki K; Ui T; Nagano A; Hino A; Arano Y
Sci Rep; 2019 Oct; 9(1):15284. PubMed ID: 31653903
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression.
Hennrich U; Seyler L; Schäfer M; Bauder-Wüst U; Eisenhut M; Semmler W; Bäuerle T
Bioorg Med Chem; 2012 Feb; 20(4):1502-10. PubMed ID: 22264762
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the radiosynthesis of [
Ghai A; Singh B; Li M; Daniels TA; Coelho R; Orcutt K; Watkins GL; Norenberg JP; Cvet D; Schultz MK
Appl Radiat Isot; 2018 Oct; 140():333-341. PubMed ID: 30138815
[TBL] [Abstract][Full Text] [Related]
13. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
14. Syntheses and evaluation of
Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071
[TBL] [Abstract][Full Text] [Related]
15. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
Antunes P; Ginj M; Zhang H; Waser B; Baum RP; Reubi JC; Maecke H
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):982-93. PubMed ID: 17225119
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.
Ujula T; Huttunen M; Luoto P; Peräkylä H; Simpura I; Wilson I; Bergman M; Roivainen A
Bioconjug Chem; 2010 Sep; 21(9):1612-21. PubMed ID: 20795647
[TBL] [Abstract][Full Text] [Related]
17. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
18. 68Ga-labelled DOTA-derivatised peptide ligands.
Meyer GJ; Mäcke H; Schuhmacher J; Knapp WH; Hofmann M
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1097-104. PubMed ID: 15029459
[TBL] [Abstract][Full Text] [Related]
19. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
[TBL] [Abstract][Full Text] [Related]
20. AMD3100: A Versatile Platform for CXCR4 Targeting (68)Ga-Based Radiopharmaceuticals.
Poty S; Gourni E; Désogère P; Boschetti F; Goze C; Maecke HR; Denat F
Bioconjug Chem; 2016 Mar; 27(3):752-61. PubMed ID: 26886512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
